现代中西医结合杂志
現代中西醫結閤雜誌
현대중서의결합잡지
MODERN JOURNAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE
2014年
33期
3655-3657,3661
,共4页
崔佳%朱成功%赵莹莹%解建国
崔佳%硃成功%趙瑩瑩%解建國
최가%주성공%조형형%해건국
原发性肝癌%解氏肝癌 2 号方%H22 细胞株%Bcl -2%Bax
原髮性肝癌%解氏肝癌 2 號方%H22 細胞株%Bcl -2%Bax
원발성간암%해씨간암 2 호방%H22 세포주%Bcl -2%Bax
primary liver cancer%Xie’s liver cancer prescription NO.2%cell line H22%Bcl -2%Bax
目的:研究解氏肝癌2号方对肝癌 H22荷瘤小鼠的抗肿瘤及免疫调节作用。方法建立 H22肝癌小鼠模型,随机分为模型组、解氏肝癌2号方组、中药半枝莲组和白细胞介素-2(IL -2)组共4组,每组10只,并予第2天始给予相应药物灌胃。第15天处死小鼠,取出肿瘤,称取瘤质量,计算抑瘤率、胸腺指数、脾指数等指标,并通过免疫组化的方法检测凋亡相关蛋白 Bcl -2和 Bax 的表达情况。结果①解氏肝癌2号方组与 IL -2组体质量增加更为明显。②解氏肝癌2号方组的抑瘤率与中药半枝莲组相仿,二者均显著高于 IL -2组。③解氏肝癌2号方组与 IL -2组的胸腺指数和脾脏指数无明显差异,均明显高于中药半枝莲组及模型组。④解氏肝癌2号方组 Bcl -2水平与中药半枝莲组相仿,低于模型组和 IL -2组,模型组最高;而 Bax 水平正好相反,解氏肝癌2号方组与中药半枝莲组均高于模型组和 IL -2组,模型组最低。结论解氏肝癌2号方能明显改善小鼠的一般生活状态,增加小鼠体质量,对肿瘤有明显抑制作用,并且下调肝癌 H22荷瘤小鼠的凋亡相关蛋白 Bcl -2的表达,上调 Bax 的表达,能够明显改善机体免疫功能,减轻恶性肿瘤对机体的损害,减轻病痛,使人体与癌肿长期共存,互不侵犯。本实验为临床“带瘤生存”理念提供了坚实的理论基础。
目的:研究解氏肝癌2號方對肝癌 H22荷瘤小鼠的抗腫瘤及免疫調節作用。方法建立 H22肝癌小鼠模型,隨機分為模型組、解氏肝癌2號方組、中藥半枝蓮組和白細胞介素-2(IL -2)組共4組,每組10隻,併予第2天始給予相應藥物灌胃。第15天處死小鼠,取齣腫瘤,稱取瘤質量,計算抑瘤率、胸腺指數、脾指數等指標,併通過免疫組化的方法檢測凋亡相關蛋白 Bcl -2和 Bax 的錶達情況。結果①解氏肝癌2號方組與 IL -2組體質量增加更為明顯。②解氏肝癌2號方組的抑瘤率與中藥半枝蓮組相倣,二者均顯著高于 IL -2組。③解氏肝癌2號方組與 IL -2組的胸腺指數和脾髒指數無明顯差異,均明顯高于中藥半枝蓮組及模型組。④解氏肝癌2號方組 Bcl -2水平與中藥半枝蓮組相倣,低于模型組和 IL -2組,模型組最高;而 Bax 水平正好相反,解氏肝癌2號方組與中藥半枝蓮組均高于模型組和 IL -2組,模型組最低。結論解氏肝癌2號方能明顯改善小鼠的一般生活狀態,增加小鼠體質量,對腫瘤有明顯抑製作用,併且下調肝癌 H22荷瘤小鼠的凋亡相關蛋白 Bcl -2的錶達,上調 Bax 的錶達,能夠明顯改善機體免疫功能,減輕噁性腫瘤對機體的損害,減輕病痛,使人體與癌腫長期共存,互不侵犯。本實驗為臨床“帶瘤生存”理唸提供瞭堅實的理論基礎。
목적:연구해씨간암2호방대간암 H22하류소서적항종류급면역조절작용。방법건립 H22간암소서모형,수궤분위모형조、해씨간암2호방조、중약반지련조화백세포개소-2(IL -2)조공4조,매조10지,병여제2천시급여상응약물관위。제15천처사소서,취출종류,칭취류질량,계산억류솔、흉선지수、비지수등지표,병통과면역조화적방법검측조망상관단백 Bcl -2화 Bax 적표체정황。결과①해씨간암2호방조여 IL -2조체질량증가경위명현。②해씨간암2호방조적억류솔여중약반지련조상방,이자균현저고우 IL -2조。③해씨간암2호방조여 IL -2조적흉선지수화비장지수무명현차이,균명현고우중약반지련조급모형조。④해씨간암2호방조 Bcl -2수평여중약반지련조상방,저우모형조화 IL -2조,모형조최고;이 Bax 수평정호상반,해씨간암2호방조여중약반지련조균고우모형조화 IL -2조,모형조최저。결론해씨간암2호방능명현개선소서적일반생활상태,증가소서체질량,대종류유명현억제작용,병차하조간암 H22하류소서적조망상관단백 Bcl -2적표체,상조 Bax 적표체,능구명현개선궤체면역공능,감경악성종류대궤체적손해,감경병통,사인체여암종장기공존,호불침범。본실험위림상“대류생존”이념제공료견실적이론기출。
Objective It is to observe the anti -tumor and immunoregulation effect of Xie’s liver cancer prescription NO. 2 in mice with H22 liver cancer.Methods The H22 liver cancer mice model were established and divided into 4 groups ran-domly, including model group (group A), Xie’s liver cancer prescription NO.2 group (group B), herba scutellariae barba-tae group (group C) and IL -2 group (group D), 10 mouse in each group.All animal were given corresponding medicine by stomach start on the next day.On the 15th day, the mouse were killed and got the tumor out to weigh the tumor, calculate the tumor inhibition rate, thymus index, spleen index and other related indexes, and the expression of Bcl -2 and Bax were detec-ted by immunohistochemistry.Results ①The weight of body were increased more obviously in group B and group D.②The tumor inhibition rate of group B was similar as that of group C, and both were higher than that of group D.③There were no significant differences in thymus index and spleen index between group B and group D, but they were both significantly higher than that of group A and group C.④The Bcl -2 content of group B was similar as that of group C, and both were lower than that of group A and group D.The content of Bcl -2 of group A was the highest.While the result of Bax content was the oppo-site, both data of group B and group C were higher than the other two groups’ and the content of group A was the lowest. Conclusion Xie’s liver cancer prescription NO.2 can improve the survival situation of tumor -bearing mice, increase the body weight of mice and effectively inhibit the tumor.Also, it can lower the Bcl -2 gene expression of tumor -bearing mice with liver cancer H22 and upper the Bax gene expression.It can significantly improve the immune function, alleviate the dam-age to the body of malignant tumor, and make human body and the cancer long -term coexistence, mutual non -aggression. This experiment provides a solid theoretical basis for the clinical "survival"concept.